183 related articles for article (PubMed ID: 36198529)
1. [Novel therapies in AML and their resistance mechanisms].
Takahashi K
Rinsho Ketsueki; 2022; 63(9):1052-1057. PubMed ID: 36198529
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
3. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia.
Yilmaz M; Daver N
Drugs; 2019 Jul; 79(11):1177-1186. PubMed ID: 31222627
[TBL] [Abstract][Full Text] [Related]
4. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
5. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.
Gebru MT; Wang HG
J Hematol Oncol; 2020 Nov; 13(1):155. PubMed ID: 33213500
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance in mutant FLT3-positive AML.
Weisberg E; Sattler M; Ray A; Griffin JD
Oncogene; 2010 Sep; 29(37):5120-34. PubMed ID: 20622902
[TBL] [Abstract][Full Text] [Related]
8. FLT3 inhibitors in AML: are we there yet?
Sudhindra A; Smith CC
Curr Hematol Malig Rep; 2014 Jun; 9(2):174-85. PubMed ID: 24682858
[TBL] [Abstract][Full Text] [Related]
9. Midostaurin approved for FLT3-mutated AML.
Levis M
Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144
[TBL] [Abstract][Full Text] [Related]
10. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
[TBL] [Abstract][Full Text] [Related]
11. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.
Grunwald MR; Levis MJ
Int J Hematol; 2013 Jun; 97(6):683-94. PubMed ID: 23613268
[TBL] [Abstract][Full Text] [Related]
12. Molecularly targeted therapies for acute myeloid leukemia.
Stein EM
Hematology Am Soc Hematol Educ Program; 2015; 2015():579-83. PubMed ID: 26637775
[TBL] [Abstract][Full Text] [Related]
13. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Megías-Vericat JE; Ballesta-López O; Barragán E; Martínez-Cuadrón D; Montesinos P
Blood Rev; 2020 Nov; 44():100675. PubMed ID: 32147087
[TBL] [Abstract][Full Text] [Related]
15. [Progress in molecularly targeted therapies for acute myeloid leukemia].
Tomita A
Rinsho Ketsueki; 2015 Feb; 56(2):130-8. PubMed ID: 25765792
[TBL] [Abstract][Full Text] [Related]
16. The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells.
Hospital MA; Green AS; Lacombe C; Mayeux P; Bouscary D; Tamburini J
Blood; 2012 Feb; 119(7):1791-2. PubMed ID: 22343664
[No Abstract] [Full Text] [Related]
17. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
18. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
[TBL] [Abstract][Full Text] [Related]
19. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
Kiyoi H; Kawashima N; Ishikawa Y
Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
[TBL] [Abstract][Full Text] [Related]
20. Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities.
Gołos A; Góra-Tybor J; Robak T
Expert Opin Investig Drugs; 2023 Jan; 32(1):53-67. PubMed ID: 36669827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]